id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9632 R34251 |
Meador (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2020 | Fetal loss (Spontaneous miscarriages and fetal death) | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.16 [0.06;23.67] C excluded (control group) |
0/14 3/113 | 3 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9633 R34255 |
Meador (Carbamazepine) (Controls unexposed, disease free), 2020 | Fetal loss (Spontaneous miscarriages and fetal death) | 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No |
7.81 [0.15;410.24] C excluded (control group) |
0/14 0/106 | 0 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9634 R34259 |
Meador (Carbamazepine) (Controls unexposed, sick), 2020 | Fetal loss (Spontaneous miscarriages and fetal death) | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 1.07 [0.02;58.03] C | 0/14 0/15 | 0 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9685 R34470 |
Trivedi (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2018 | Spontaneous fetal loss (both spontaneous abortion before 20 weeks of gestation and stillbirths occurring after 20 weeks of gestation) | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.68 [0.23;2.03] C excluded (control group) |
27/465 4/48 | 31 | 465 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9686 R34471 |
Trivedi (Carbamazepine) (Controls unexposed, sick), 2018 | Spontaneous fetal loss (both spontaneous abortion before 20 weeks of gestation and stillbirths occurring after 20 weeks of gestation) | 1st trimester | prospective cohort | unexposed, sick | Adjustment: Yes | 3.53 [1.15;10.90] | 27/465 5/178 | 32 | 465 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9687 R34472 |
Vajda (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2018 | Intrauterine foetal death | throughout pregnancy | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.30 [0.64;2.63] C excluded (control group) |
19/404 14/382 | 33 | 404 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9688 R34473 |
Vajda (Carbamazepine) (Controls unexposed, sick), 2018 | Intrauterine foetal death | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 8.00 [1.08;59.25] | 19/404 1/170 | 20 | 404 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9635 R34262 |
Miškov (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2016 | Fetal loss | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.50 [0.24;9.35] C excluded (control group) |
2/13 4/37 | 6 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9636 R34266 |
Miškov (Carbamazepine) (Controls unexposed, disease free), 2016 | Fetal loss | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
60.71 [2.73;1349.00] C excluded (control group) |
2/13 0/128 | 2 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9637 R34270 |
Miškov (Carbamazepine) (Controls unexposed, sick), 2016 | Fetal loss | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 1.67 [0.06;43.79] C | 2/13 0/4 | 2 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9597 R33986 |
Arkilo (Carbamazepine), 2015 | Unsuccessful pregnancies (miscarriages/stillbirths) | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 2.36 [0.35;15.93] C | 3/17 2/24 | 5 | 17 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9684 R34468 |
Tomson (Carbamazepine), 2015 | Intrauterine death | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.08 [0.85;1.37] C | 144/1,713 150/1,910 | 294 | 1,713 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9655 R34371 |
Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 | Intrauterine death | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.81 [0.59;1.11] C | 67/1,718 105/2,198 | 172 | 1,718 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9663 R34404 |
Holmes (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2011 | Intrauterine death as a whole | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No Controls: mixed indications |
1.48 [0.57;3.85] C excluded (control group) |
8/573 9/948 | 17 | 573 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9675 R34441 |
Holmes (Carbamazepine) (Controls unexposed, disease free), 2011 | Intrauterine death as a whole | 1st trimester | prospective cohort | unexposed, disease free | Adjustment: No | 2.68 [0.33;21.54] C | 8/573 1/190 | 9 | 573 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9631 R34247 |
Meador (Carbamazepine), 2006 | Fetal death (early and late intrauterine deaths) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 8.32 [0.44;156.51] C | 4/110 0/98 | 4 | 110 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9662 R34396 |
Diav-Citrin (Carbamazepine), 2001 | Intrauterine deaths as a whole | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No Matched | 1.30 [0.68;2.47] C | 18/108 28/210 | 46 | 108 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 10 studies | 1.29 [0.91;1.83] | 584 | 5,135 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Controls unexposed, sick; 2: Carbamazepine) (Controls unexposed, sick; 3: Carbamazepine) (Controls unexposed, sick; 4: Carbamazepine) (Controls unexposed, sick; 5: Carbamazepine; 6: Carbamazepine; 7: Carbamazepine) (Controls exposed to Lamotrigine, sick; 8: Carbamazepine) (Controls unexposed, disease free; 9: Carbamazepine; 10: Carbamazepine;
Asymetry test p-value = 0.0214 (by Egger's regression)
slope=-0.1681 (0.1190); intercept=1.1903 (0.4173); t=2.8526; p=0.0214
excluded 9663, 9635, 9636, 9685, 9687, 9632, 9633